---
title: "Centrus Reports Second Quarter 2026 Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295017018.md"
description: "In the most recent quarter, the company generated a revenue of $176.1 million, exhibiting a growth from the previous quarter’s revenue of $154.5 million. The GAAP net income for this period was $16.8 million, a decrease from $28.9 million in Q2 2025. However, the non-GAAP adjusted net income stood at $38.7 million, showcasing an increase from $34.5 million in Q2 2025."
datetime: "2026-08-05T20:55:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295017018.md)
  - [en](https://longbridge.com/en/news/295017018.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295017018.md)
generator: "portal-rs"
---

# Centrus Reports Second Quarter 2026 Results

In the most recent quarter, the company generated a revenue of $176.1 million, exhibiting a growth from the previous quarter’s revenue of $154.5 million. The GAAP net income for this period was $16.8 million, a decrease from $28.9 million in Q2 2025. However, the non-GAAP adjusted net income stood at $38.7 million, showcasing an increase from $34.5 million in Q2 2025.

### Related Stocks

- [LEU.US](https://longbridge.com/en/quote/LEU.US.md)
- [LEUX.US](https://longbridge.com/en/quote/LEUX.US.md)

## Related News & Research

- [Centrus Energy adopts 2026 incentive plan with performance RSUs worth up to $5 million for CEO Vexler](https://longbridge.com/en/news/296269758.md)
- [LEU: Q2 2026 delivered strong revenue, backlog growth, and expansion progress amid industry tailwinds](https://longbridge.com/en/news/295023179.md)
- [Cel-Sci GAAP EPS of -$0.47](https://longbridge.com/en/news/296114461.md)
- [Aptorum Group GAAP EPS of -$1.60](https://longbridge.com/en/news/296654186.md)
- [XORTX Therapeutics Inc. GAAP EPS of -$1.05](https://longbridge.com/en/news/296650983.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**